Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone or no treatment, following a 24-week first-line induction with FP, oxaliplatin (Ox) and Bev for patients with metastatic colorectal cancer: Mature data and subgroup analysis of the AIO KRK 0207 phase III study
S. Hegewisch-Becker
Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone or no treatment, following a 24-week first-line induction with FP, oxaliplatin (Ox) and Bev for patients with metastatic colorectal cancer: Mature data and subgroup analysis of the AIO KRK 0207 phase III study
S. Hegewisch-Becker